Hon CHRIS HIPKINS: Of that $1.4 billion, $964.3 million of that is for the advance purchase and the COVAX facility purchases that will support equitable access to COVID-19 vaccines; $66.3 million covers the cost of specialist vaccine equipment, including syringes and related vaccine storage facilities and transport; the remaining $356.9 million has been allocated for technology to support the roll-out, funding for DHBs, ongoing support for Medsafe, and to stand up community immunisation centres. 